ProductUnclaimedBiotechHealthOncology

Porustobart

by Solstice Oncology

Engineered CTLA-4 antibody for neoadjuvant immuno-oncology

solsticeoncology.com

Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.

About

Porustobart is Solstice Oncology's investigational second-generation heavy-chain-only CTLA-4 antibody being studied in combination with anti–PD-1 therapy in the neoadjuvant setting, starting with MSS stage III colon cancer.

Added via
web
Ownership
unclaimed

Where to go

For people

For agents

Product details

Product kind
Other

← Directory